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Abstract
Many clients who undergo methadone maintenance (MM) treatment for heroin and other opiate
dependence prefer abstinence from methadone. Attempts at methadone detoxification are often
unsuccessful, however, due to distressing physical as well as psychological symptoms. Outcomes
from a MM client who voluntarily participated in an Acceptance and Commitment Therapy (ACT)
– based methadone detoxification program are presented. The program consisted of a 1-month
stabilization and 5-month gradual methadone dose reduction period, combined with weekly
individual ACT sessions. Urine samples were collected twice weekly to assess for use of illicit
drugs. The participant successfully completed the program and had favorable drug use outcomes
during the course of treatment, and at the one-month and one-year follow-ups. Innovative behavior
therapies, such as ACT, that focus on acceptance of the inevitable distress associated with opiate
withdrawal may improve methadone detoxification outcomes.
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The burden of illicit opiate use is substantial, including high morbidity and mortality rates,
health care utilization costs, legal involvement, family discord, and lost productivity
(Amato, Davoli, Ferri, Growing, & Perucci, 2004). To date, methadone maintenance (MM)
is the treatment of choice for opiate dependence. Patients typically enter MM treatment after
heroin or other opiate dependence is well-established, with the average length of stay at any
particular clinic being 1-2 years (D'Aunno, Folz-Murphy, & Lin 1999). Many MM patients
transfer from clinic to clinic, however, remaining on methadone for many years, and, for
some, the remainder of their lives. MM is a successful treatment as it is associated with
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decreases in client's illicit drug use and health risk behaviors, as well as significant
improvement in social functioning (Simpson, Joe, & Bracy, 1982). Yet, MM remains
controversial (Magura & Rosenblum, 2001). Many professionals believe that substituting
one addiction for another is not ethically or therapeutically acceptable. In addition, long-
term MM treatment incurs significant financial burden, restrictions in daily activities, and
unpleasant stigma. The majority of MM clients state a preference for abstinence (e.g., Lenne
et al., 2001), and a number of them request detoxification or attempt to detoxify themselves
(Latowsky, 1996).
The primary obstacle, however, lies in the physical and psychological discomfort
accompanying methadone detoxification (Magura & Rosenblum, 2001). Withdrawal from
methadone results in severe and protracted physiological symptoms (e.g., nausea, diarrhea,
bone pain). Methadone withdrawal experiences are reported to be even more severe than
heroin withdrawal (e.g., Gossop & Strang, 1991), with failure to successfully taper off
methadone being the rule, rather than the exception (Magura & Rosenblum, 2001). Adverse
psychological experiences are also deterrents to detoxification. Most prominent is an intense
fear related to experiencing detoxification symptoms (e.g., Eklund, Hiltunen, Melin, &
Borg, 1997). Long before symptoms are physically present, anxiety and worry about
impending pain and suffering are reported. Consequently, clients who report detoxification
phobia are more likely to stay in MM treatment longer and make fewer detoxification
attempts (Milby et al., 1994). MM clients who have failed methadone detoxification report
that anticipation or fear of intense withdrawal, rather than actual physical symptoms, was the
predominant reason for the discontinuation of detoxification (Berger & Schwegler, 1973).
Thus, relapse to opiates or other illicit substances and premature termination of
detoxification are the most common outcomes especially when clients undergo rapid
methadone dose reduction in a poorly supervised outpatient setting (Gossop, Marsden,
Stewart, & Treacy, 2001). Many experts, for this reason, advocate for life-long MM
treatment. Methadone detoxification is typically patient-initiated and may only be
recommended to a selected group of clients who have a relatively stable life without the
current use of illicit drugs.
Behavioral strategies, such as systematic desensitization (e.g., Hollands & Turecek, 1980)
and contingency management (e.g., Robles, Stitzer, Strain, Bigelow, & Silverman, 2002)
have been tested to improve detoxification outcomes. These studies revealed equivocal
results (e.g., short-term effects), however. Given the inevitability of physical and
psychological struggles in methadone detoxification, these treatments could possibly be
made more effective by teaching clients skills to function more effectively while
experiencing these difficulties. In other words, the problem in this context may not be
simply the presence or intensity of detoxification fears and withdrawal symptoms, but the
ways in which individuals act on their distressing psychological experiences.
This line of reasoning overlaps with a contemporary behavioral process purported to
underlie psychopathology, psychological inflexibility (PI; Hayes, Luoma, Bond, Masuda, &
Lillis, 2006). Psychological inflexibility is defined as one's limited and rigid behavioral
repertoires in the presence of negatively evaluated private events (thoughts, feelings, bodily
sensation, etc), and is the overarching process targeted by Acceptance and Commitment
Therapy (ACT; Hayes, Strosahl, & Wilson, 1999). According to the model, the inflexible
patterns are due to the domination of unavailing avoidance- and control-based coping
strategies, collectively referred to as experiential avoidance (Hayes et al., 2006). The
domination of these behavioral patterns is thought to suppress value-directed and
constructive behaviors. The ACT model suggests that the primary problem of negative affect
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is its function, rather than its existence per se. In other words, these events are problematic
only because they occasion problematic behavior.
Research has shown that PI is linked to a wide range of psychological problems and
functions as a mediator of treatment outcomes (Hayes et al., 2006). Recent studies suggest
that PI may be a key process involved in the methadone detoxification process. Individuals
with chronic opiate use tend to have greater fear of anxiety and anxiety-related sensation
(e.g., Lejuez, Paulson, Daughters, Bornovalova, & Zvolensky, 2006). Those undergoing
MM treatment have less distress tolerance than those who do not have substance use
problems and display limited behavioral repertoires (i.e., predominantly avoidance
strategies) when experiencing negative affect (Compton, Charuvastra, & Ling, 2001).
Several studies, ranging from case report studies to randomized controlled trials, have
shown promising outcomes with ACT in substance use problems (e.g., Gifford et al., 2004;
Hayes, Wilson, et al., 2004; Twohig, Schoenberger, & Hayes, 2007; Heffner, Eifert, Parker,
Hernandez, & Sperry, 2003). In one randomized controlled trial (Gifford et al., 2004), ACT
was compared to Nicotine Replacement Therapy. Results revealed that ACT participants
were more likely to remain abstinent at one-year follow-up (35% vs. 10%). The study also
showed that smoking-related PI mediated smoking outcomes, while negative affect and
withdrawal symptoms did not. These findings suggest that an individual's approach to
distress related to smoking cessation, rather than their absolute level of emotional discomfort
or distress, may be a crucial factor contributing to treatment outcome. ACT components
likewise showed considerable promise in a recent pilot study examining a multicomponent
distress tolerance treatment for early lapsing smokers (Brown et al., 2008).
The impact of ACT on substance use among poly-substance-abusing MM clients has also
been investigated (Hayes, Wilson et al. 2004). Results revealed that compared to MM
treatment alone, the 16-week ACT combined with MM resulted in lower opiate use (61% vs.
28%) and lower total drug use (50% vs. 12%) at 6-month follow up.
To date, no study has examined whether ACT facilitates methadone detoxification. We
present a case report of an adult MM client who received weekly individual ACT adjunctive
to a 24-week gradual methadone dose reduction program. The case investigation has three
purposes: (1) To illustrate how an ACT model of treatment can be applied to methadone
detoxification; (2) To evaluate the effect of a 6-month ACT-enhanced methadone dose
reduction program on treatment completion, opiate use, and the use of other illicit drugs; (3)
To gather preliminary data on the relation between PI and treatment outcomes. If the ACT
model were supported, the client would successfully complete the program, while showing a
reduction in PI.
Case Description
To protect the client's confidentiality, the identity of the client was altered. The client was a
57-year-old Hispanic American male with a high school education. He lived in a house with
his second wife and her two teenage daughters in a large Southern US city. The client also
had two biological children, a son and daughter, from his first marriage. They were now
adults and living independently elsewhere. The client's first wife died 7 years prior from
Hepatitis C contracted through heroin use. Five years after her death he married his current
wife. At the time of intake, the client was employed full-time at an oil/gas factory.
Intake screening with the Structured Clinical Interview for DSM (SCID: First, Spitzer,
Gibbon, & Williams, 2002) and the Addiction Severity Index (ASI: McLellan, Luborsky,
Woody, & O'Brien, 1980) revealed that the client had a history of dependence on alcohol
(sustained full remission) and opiates (with agonist replacement therapy), and abuse of
Stotts et al. Page 3
Cogn Behav Pract. Author manuscript; available in PMC 2010 July 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
cocaine. The client began drinking alcohol during his adolescent years, eventually drinking
12-24 drinks daily. At age 32, he attended a residential alcohol treatment program, which
resulted in complete abstinence from alcohol thereafter. Many other substances were used
periodically from adolescence through his 40s including diazepam, barbiturates (20 yrs),
marijuana (20 years), amphetamines/ methamphetamine (10 years), cocaine (10 years),
LSD/glue (3 years). For a period of 17 years he reported using more than one substance
daily. Beginning at age 40, the client began using heroin almost daily for 10 years and then
entered MM treatment. He was at the MM clinic for 7 years prior to voluntarily transferring
to our methadone dose reduction program. Over the last two years the client attempted
methadone detoxification at his MM clinic twice unsuccessfully; each time resuming his
original dosing schedule within a few weeks. The client attributed the discontinuation of
detoxification to intense withdrawal symptoms and emotional distresses. He reported being
nervous and jittery and experienced increased sweating, insomnia, and depression. No other
Axis I or II psychiatric disorders were identified. However, his score on the Beck
Depression Inventory-II (BDI-II; Beck, 1996) was 10, indicating that he experienced slightly
elevated levels of depression at the time of intake.
The client was a highly appropriate candidate for methadone detoxification. He had a
relatively stable life in that he was married, employed, and had been abstinent from alcohol
and other drugs for at least 10 years (intake urine screen was negative for all substances
except methadone). He displayed strong motivation for methadone detoxification, stating
lack of freedom as his major motive. Nevertheless, he reported that methadone
detoxification seemed extremely challenging due to withdrawal symptoms and previous lack
of success. He had a long and extensive substance use history, and thus his coping seemed to
be limited to avoidance and control-oriented strategies, such as distraction and positive-self
talk; strategies intended to escape or eliminate negative thoughts, feelings, and bodily
sensations. Given the apparent deficit of alternative skills, it was predicted that he would
likely report withdrawal symptoms and psychological distress relatively early in the course
of treatment. His narrow repertoire of coping skills, however, seemed balanced by his strong
self-reported desire to pursue personal values (e.g., being free).
Setting and Staff
The ACT-enhanced methadone detoxification was conducted in a university substance abuse
research center staffed by interdisciplinary treatment team (e.g., nurses, psychiatrist,
pharmacist, masters-level therapists, principal investigator, and therapist supervisor). The
ACT therapy was conducted by a masters-level therapist with a cognitive-behavior therapy
background who had worked in the field of substance use treatment for several years. She
was trained and supervised in doing ACT by the second and third authors and on substance
abuse treatment issues by the first author.
Assessment
Substance Use—Throughout the course of the dose reduction program, the client's
substance use and subjective withdrawal experience were measured twice weekly and at the
one-month and one-year follow-up assessments. Substance use was measured using
Qualitative urine toxicology screens for the presence of cocaine, heroin, amphetamines,
barbiturates, benzodiazepines, tetrahydrocannabinol, caffeine, nicotine, and methadone.
Breath alcohol concentration (BAC) in breath samples were also measured using an alcohol
meter (Alco Sensor 3) which detects recent alcohol use.
Subjective Withdrawal Experience—The client's withdrawal experience was assessed
weekly and at both follow-up time points using the Subjective Opiate Withdrawal Scale
(SOWS; Handelsman, Cochrane, Aronson, Ness, Rubinstein, & Kanof, 1987). The SOWS
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contains items to rate the intensity of 16 different withdrawal symptoms using a scale of 0
(not at all) to 4 (extremely), with greater scores suggesting greater subjective withdrawal
experiences. The SOWS has established psychometric properties and provides a sensitive
measure of withdrawal severity and changes in withdrawal severity (Gossop, 1990).
Interclass correlations assessing test-retest reliability were significant at the p = .001 level
(Handelsman et al., 1987). The SOWS items reflect: feeling sick, stomach cramps, muscle
spasms/twitching, feelings of coldness, heart pounding/racing, muscle tension/feeling tense,
aches and pains, yawning, runny eyes, and insomnia/sleeping problems.
Negative Affect—The BDI-II (Beck, 1996), one of the most widely used self-report
measures of depression, was administered at pretreatment and at both one-month and one-
year follow-up time points to assess the levels of depression.
The Detoxification Fear Survey Schedule (DFSS-27: Gentile & Milby, 1992) is a 27-item
measure of fear of relapse, withdrawal symptoms, and AIDS rated on a Likert scale. The
DFSS has demonstrated adequate internal consistency, ranging from .74 to .96 and good
two-week test-retest reliability (r = .77). Based on a sensitivity analysis, a cut-off score of 70
was selected for identifying diagnostically significant and severe detoxification fear. The
DFSS was administered monthly and at one month and one year follow-up time points.
Psychological Inflexibility—The Acceptance and Action Questionnaire (AAQ; Hayes,
Strosahl, et al., 2004) was administered monthly and at the follow-up time points to measure
level of psychological inflexibility (PI) or inflexible behavior repertoires, such as
experiential avoidance, in the presence of negatively evaluated private events (thoughts,
feelings, bodily sensation, etc). The AAQ (i.e., 9-item vesion) is a 7-point Likert scale with
adequate internal consistency (alpha of .70; Hayes, Strosahl, et al., 2004).
Program Overview
Methadone Dose Reduction Schedule
Based on a previous agonist-replacement therapy detoxification study using levo-alpha
acetyl methadol (LAAM; Grabowski et al., 2005), a 24-week detoxification period was
selected, beginning with a 4-week stabilization phase, in which methadone doses were
adjusted based on client weight (1.2 mg/kg). The dose stabilization phase was then followed
by a 20-week linear dose reduction phase. The client was dosed twice per week at the
treatment-research clinic, with “take home” doses provided for the intervening days. This
client's initial dose was 120 mg. Some flexibility in the dose reduction schedule was
permitted to accommodate severe withdrawal and medical concerns. For example, the
client's dose was held steady for an extra week in the last month of the detoxification due to
an increase in blood pressure.
Acceptance and Commitment Therapy
The present ACT protocol was largely drawn from existing ACT manuals (e.g., Hayes et al.,
1999) and the previous ACT project on polysubstance use (Hayes, Wilson, et al., 2004) (see
Table 1). Modifications were made to reflect issues specific to methadone detoxification.
The ACT protocol consisted of 24 50-minute sessions delivered weekly beginning in the
stabilization period and continuing through the dose reduction period. Each session typically
started with a 5 to 10 minute mindfulness exercise (e.g., breathing, sitting still, noticing and
observing thoughts, feelings, bodily sensations). Session specific components were
introduced using the client's personal experiences related to the methadone dose reduction
and/or other life events. Implementation and rationale for the four overarching ACT
intervention components are described generally in Table 1 and more specifically below.
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Values Clarification—In contrast with several ACT protocols, values-focused
interventions were introduced to the client early, prior to beginning the methadone dose
reduction, for several reasons. One reason was to firmly establish ACT congruent treatment
goals and therapeutic rationale. Clarifying the client's personal values gave the therapy an
overarching purpose based on what the client deemed most important. Methadone
detoxification itself was not the end-goal, but a step in the direction of a less constricted and
ultimately more meaningful life. Second, values-clarification was introduced during the
stabilization period to increase the client's motivation and commitment to enter into
methadone detoxification. Finally, the client's expected trajectory of emotional and
physiological distresses throughout the course of methadone detoxification was taken into
account for the timing of value-focused interventions. Greater emotional and physiological
distress was expected as his dose was decreased. Strengthening personal values early in the
treatment was thought to increase the probability of program completion.
Linking the costs of previous and current substance use (and associated shame and guilt)
with personal values was extremely powerful in the value-focused phase. For example, the
client reported that the loss of his first wife was a most difficult and painful experience for
him (e.g., strong sense of guilt for introducing her to heroin). When the client emotionally
disclosed his pain from the loss, the therapist gently said to the client:
“It seems like you have this pain and guilt because you cared about her. You cared
about intimacy, family, and trust. You still do. These are very important to you.
There are values under the pain and guilt. Perhaps you are about to start methadone
detox for this”.
The client was well-connected to the perspective and reported his willingness to commit to
methadone detoxification in order to have a value-directed life.
Shifting Perspectives—Sessions 5 through 9 primarily focused on shifting perspectives
from avoiding and controlling aversive private events (i.e., detoxification fear, feelings of
uncertainty, fear of failure, physical withdrawal experience) to letting go of struggles (e.g.,
psychological acceptance). This was one of the most challenging tasks for the client. He
seemed to believe, as most people do, that negative private experiences were likely to
prevent him from staying committed to value-directed activities, including methadone
detoxification. Given this belief, he tried not to have these events by engaging in distraction
and positive self-talk (e.g., “I'll be OK and stay positive!”), which seemed quite logical.
However, these strategies were highly unlikely to help him through the detoxification
process because distressing private experiences were simply inevitable. Further, avoidance
and control strategies and their failure to alleviate suffering were likely to make these events
worse, jeopardizing detoxification success. The only way to ultimately control the physical
symptoms of withdrawal is to use methadone or heroin again. With this conceptualization, it
was extremely crucial for the client to have the shift in perspective.
We found it helpful to suggest to the client that anxiety, depression, and physical withdrawal
symptoms are expected given his history and that these experiences do not have the power to
lead to the premature termination of detoxification or relapse to heroin. After several
sessions with this focus, the client began freely admitting and sharing his feelings with the
therapist and became open to an alternative to distraction and positive self-talk.
Acceptance and Mindfulness—The stance of acceptance and mindfulness was
introduced to the client midway through the dose-reduction schedule as the client was
experiencing detoxification fears and subjective withdrawal symptoms at this time, but not
to a severe degree. For this client, more frequent voicing of his withdrawal symptoms
(sleeplessness, leg pain, upset stomach, etc) was considered an indication of increased
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psychological acceptance, relative to his previous attempts to avoid all discussion of such
experiences.
In addition to using conventional ACT metaphors and experiential exercises (see Hayes et
al, 1999), we found that the phrases “I am having the thought that…” and “I am noticing that
…” were useful to create distance from and reduce the attachment to his distressing thoughts
and feelings. These techniques helped to increase the client's psychological openness and
nonjudgmental stance toward these private events. The client learned experientially that
withdrawal symptoms and negative affect did not automatically lead him to substance use or
premature discontinuation of therapy.
Commitment to Value-Directed Life—Sessions 18 through 24 focused on maintaining
an ongoing commitment to value-directed actions, including methadone dose reduction. By
week 18 of the therapy, the reduced dose of methadone resulted in highly distressing
withdrawal symptoms (e.g., bone pain, nausea, sweating, insomnia). The client's experience
of psychological and physical struggles (e.g., uncertainty, fear, pain) were identified,
validated and normalized, and put into context with the aspects of life he found most
important (i.e., values). Personal values were revisited, including his commitment to
finishing the program, to strengthen value-directed activities. Client-initiated value
congruent actions (e.g., calling his biological son) were especially reinforced. In session 23
and 24, the client continued to report the gradually intensified experience of withdrawal
symptoms. Nevertheless, he also continued to report his commitment to methadone
detoxification and progress in communicating with his wife, stepdaughters, and biological
children, a self-identified target behavior. In the last session, progress in treatment and plan
for his future were discussed, and the individual therapy session was terminated.
At the one-month follow-up, the client reported he was doing well, with only a few residual
withdrawal symptoms, mainly insomnia. At one year, he and his 2nd wife were in the
process of divorcing. He reported increased anxiety related to this situation, but overall, he
reported functioning well.
Results
Withdrawal Symptoms and Negative Affect
At intake, the client's methadone dose remained stable at 120 mg, yet his SOWS score
indicated moderate degrees of perspiration, teary eyes, running nose, and hot flushes and
mild degrees of muscle aches (see Figure 1). Throughout the course of the 24-week
methadone dose reduction program, his SOWS scores did not exceed pretreatment levels,
despite fluctuation (i.e., ranging from 1 to 13). During the second half of program, his
SOWS scores indicated the presence of moderate stomach cramps, running nose, and
anxiety. At the one-month follow-up, the client reported no subjective withdrawal symptoms
in the SOWS.
The client's BDI-II score was slightly increased at the one-month follow-up relative to that
of baseline (BDI-II = 15). The client endorsed some physiological symptoms of depression
that overlapped with the withdrawal symptoms of methadone, such as fatigue and difficulty
in sleeping. Increased negative affect at post-detoxificaion is commonly reported and often
associated with relapse to opiate use (e.g., McLellan, Childress, Ehrman, O'Brien, & Pashko,
1986). In the midst of divorce process, he scored 17 on BDI-II at a one-year follow-up. He
endorsed past failure, loss of pleasure, and loss of sexual interest.
The client's DFSS scores at the various time points were low relative to the cut-off score of
70 set by Milby and colleagues. Thus, although fear was reported, the client is not part of the
Stotts et al. Page 7
Cogn Behav Pract. Author manuscript; available in PMC 2010 July 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
minority of MM clients who report diagnostically severe detoxification phobia. Visual
inspection of the data also indicates the client's levels of detoxification fears fluctuated over
time, ranging from 10 to 20 (see Figure 1).
Psychological Inflexibility
The client's AAQ-9 score at pretreatment (= 44) fell within the upper quartile (AAQ-9 > 41;
Hayes, Strosahl, et al., 2004) of PI among clinical populations. A reduction was observed in
week 4 (=38) and scores fluctuated between 40 and 35 throughout the course of dose
reduction. His average AAQ-9 score during the program was 38. The client scored 37 at the
one-month follow-up and his AAQ at the one-year follow-up was 36. Throughout the study,
his score did not go below the mean of non-Caucasian, non-clinical population (= 34.5).
Substance Use
Urine drug screen data revealed that the client was highly successful in the methadone
detoxification program. No use of any substances (i.e., cocaine, opiates, benzodiazepines,
stimulants, or psychedelics) was found during the entire 24-week program nor at the one-
month follow-up, despite significant withdrawal symptoms. Once his methadone dose
reached zero, urine data indicated that methadone was no longer present. The breath samples
revealed continued abstinence from alcohol. These findings were also consistent with his
self-report collected during the course of the program. At the one-year follow-up
assessment, the client still remained opiate-free, yet reported use of prescribed
benzodiazepines which was confirmed by the urine screen.
Discussion
Growing evidence suggests a significant impact of emotional and cognitive processes on
substance use (Marlatt & Gordon, 1985) and the potential utility of acceptance-based
intervention for substance-related problems (Hayes, Wilson, et al., 2004). The present
investigation reports on the first client enrolled in a treatment development study designed to
examine the utility of ACT-based treatment for methadone detoxification. Positive findings
indicate that, despite the well-documented odds against successful methadone detoxification,
the client completed the program without relapsing to illicit substances, maintained
abstinence from all substances at one-month follow-up, and remained opiate-free one year
post-treatment.
Particularly of relevant for ACT are the elevated subjective withdrawal symptoms reported
at intake—an entire 4 weeks before the first reduction in dose. These data underscore the
significance of the client's anticipation and fear of withdrawal and other unpleasant
detoxification experiences which manifest as anxiety-related physical symptoms. The
presence of detoxification fear was also corroborated by a higher score at intake on the
DFSS relative to other time points. These variables fluctuated throughout the course of
methadone detoxification and at follow-up points, and do not seem to have systematic
relations to substance use outcomes.
A primary target in the ACT model is the way in which a client approaches difficult private
events, not these events. ACT is designed to increase client's willing to be open to difficult
private events, while increasing value-based actions, collectively referred to as
psychological flexibility. Although the present case report did not clearly show significant
reduction in psychological inflexibility (PI), small changes in the expected direction were
noted. Future methadone detoxification studies should further explore the role of PI on
detoxification fears, subjective withdrawal symptoms, and substance use outcomes.
Stotts et al. Page 8
Cogn Behav Pract. Author manuscript; available in PMC 2010 July 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
It may seem surprising that the client chose to use benzodiazepines reportedly due to
emotional distress around the time of the one-year follow-up. This result could be viewed as
a failure of the ACT treatment or its durability, which of course are valid hypotheses.
However, the benzodiazepine use must be viewed within the context of the typical
methadone detoxification course and the client's substance use history. First, the success
rates for methadone detoxification are dismal at best. Most studies report high drop-out
rates, with few patients achieving abstinence (∼ 25%; Hall 1984). Some studies have
documented that all subjects returned to methadone or other opiate use during or in the
month following treatment (Grabowski et al., 2005). Second, this client has used substances
his entire life since adolescence to cope with the inevitable and difficult experiences of life.
He used almost every class of drug available and became physiologically dependent at
different times on alcohol and heroin. Within this context, the fact that the client went to a
doctor and acquired a prescription for an anti-anxiety medication (a behavior engaged in by
many Americans), versus returning to opiates or other illicit drugs, can arguably be viewed
as responsible behavior in the context of a distressing environmental situation (divorce)—a
significant accomplishment for this client. Of course, if the client used the medication such
that it began to interfere with pursing important life values, then the durability of ACT may
be questioned and the need for booster sessions may be entertained. If the client uses
benzodiazepines for a period of time without negative consequences in other life domains,
however, we would not consider him a treatment failure.
Methodologically, it should be noted that although reductions in PI were found using the
general, non-problem-specific AAQ, the decrements were not large. Failure to find large
changes on the general AAQ has been reported in other studies as well (e.g., Hayes et al.,
2006). A measure of psychological inflexibility related to the experience of methadone
detoxification may more precisely capture the specific fears and avoidance strategies typical
of the population. Future research is needed to develop and test such a measure.
It is important to note that there are competing explanations for treatment success. The first
factor is simply age. The client was 57 years old, and based on the typical course of
substance abuse, he was more likely to achieve abstinence from drugs compared to
substance users in younger age groups. It is important to note, however, that he failed
detoxification twice in very recent years, and that many other clients in our substance abuse
clinic of similar age have not succeeded to this level. Another factor that could influence
treatment outcome is the dose-reduction schedule. The duration of the preset dose reduction
program (i.e., 24 weeks) was longer than those used in most previous studies (e.g., 3, 6, or
12 weeks). Positive results in the present case might be simply due to the longer period of
gradual dose reduction. Perhaps even more importantly is that this client was abstinent from
all other substances upon commencing the detoxification program. This is not the norm in
the methadone-using population and may have played a large role in his ability to achieve
and maintain opiate abstinence.
Thus, further study with methodological rigor is needed to determine whether the ACT-
enhanced methadone dose reduction is effective for more complicated MM clients.
Exploration of client characteristics indicative of success with the ACT-based treatment also
seems warranted, particularly examining the relation between PI and treatment outcomes.
Given the results of the present case study, it seems worthwhile to continue research on this
promising behavioral therapy for the methadone-using population.
Finally, it is important to acknowledge that methadone dose reduction is extremely
complicated. The physical and psychological distress experienced by these clients should
not be underestimated. Although there is much research to be done to determine the
conditions under which clients will benefit from methadone detoxification, the present case
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suggests that there are MM clients who can successfully detoxify and lead drug-free lives.
Researchers have an obligation to better understand the process in order to develop more
precisely focused and effective treatments.
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Figure 1.
Methadone dose schedule, subjective opiates withdrawal experiences, detoxification fear,
and psychological inflexibility throughout the course of ACT-enhanced methadone
detoxification program.
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Table 1
Overview of ACT Components and Strategies
Sessions Components/Strategies Goals/Purposes
1-4 • Rapport Building • Client and therapist develop ACT-consistent treatment alliances and goals.
• Choosing a valued direction (value
clarification)
• Client identifies values and increases motivation for having a value-directed life
as well as commitment to methadone detoxification.
5-9 • Shifting Perspective: Control is the
problem
• Client identifies his previous and current coping styles for difficult psychological
events (e.g., anxiety, self-doubt, fear, negative bodily sensation, etc).
• Client learns these coping strategies are for controlling and avoiding negative
psychological events.
• Client learns that these coping strategies are not working well in the long run.
• Client explores ways in which control and avoidance attempts prevent him from
engaging in value-directed behaviors.
• Attempts to control and avoid problematic private events might have negative
iatrogenic effects.
• Letting go of struggle • Client notices the futility of control and avoidance attempts and is willing to
consider an alternative approach to his difficult private events (e.g., fear of
uncertainty, fear of failure).
10-18 • Acceptance and Mindfulness • Client learns psychological acceptance as an alternative to avoidance and control
attempts.
• Client chooses to be open to or to allow whatever he is experiencing as it is (i.e.,
acceptance), even difficult psychological events.
• Client learns to observe his private events.
• Client learns not to get sidetracked by his difficult psychological events.
19-24 • Commitment • Client progresses toward a committed and valuedirected life (e.g., the completion
of methadone detoxification).
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